Document is current
Any future updates will be listed below
-
Authors
Rodan, Sarah-Catherine
Meez, Noah
Lloyd-Hurwitz, Sophie
Bedoya-Pérez, Miguel A.
Suraev, Anastasia
Sommer, Natasha
Greenstien, Kayla
Maguire, Sarah
McGregor, Iain S.
-
Funding
Funding for this research was provided by:
Lambert Initiative for Cannabinoid Therapeutics
- License Information
-
More Information
Article History
Received: 12 March 2025
Accepted: 22 June 2025
First Online: 24 July 2025
Declarations
:
: The survey was approved by the Human ethics review board of the University of Sydney (2022/526) and all participants consented to participate.
: Participants provided consent for the use of their data in publication.
: AS has received consulting fees from the Medical Cannabis Industry Australia (MCIA) and Haleon (consumer healthcare subsidiary of Glaxo Smith-Kline). SM and SR has salary support from NHMRC. ISM is the Academic Director of the Lambert Initiative for Cannabinoid Therapeutics. He has served as an expert witness in various medicolegal cases involving cannabis and has received consulting fees from Medical Cannabis Industry Australia (MCIA), Althea, and Janssen. He has acted as an advisor/consultant to Kinoxis Therapeutics, Psylo, and Emyria and has had salary support from the NHMRC and from Lambert Initiative for Cannabinoid Therapeutics. He is an inventor on patents WO2017004674, WO2018107216, WO2020102857 and AU2022240104 licensed to Kinoxis Therapeutics, involving the use of novel small molecules to treat addictions, social deficits, opioid withdrawal and aggression. He is an inventor on issued patents WO2019227167 and WO2019071302 which relate to cannabinoid therapeutics. MBP, KG, NM, NS have no conflicts to declare.
